CalciMedica, Inc. (CALC)

NCM – Цена в реальном времени. Валюта: USD

0.82

+0.19 (30.29%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.76

-0.06 (-6.85%)

После закрытия: Jun 26, 2026, 7:56 PM EDT

CalciMedica, Inc. (CALC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CalciMedica, Inc. (CALC)

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Видео

No Data

Пресс-релизы

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Видео

No Data

Пресс-релизы

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Search stocks

CalciMedica, Inc. (CALC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CalciMedica, Inc. (CALC)

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Видео

No Data

Пресс-релизы

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Видео

No Data

Пресс-релизы

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates